ABSTRACT
Background Approximately 20% of ischemic strokes in the U.S. result from carotid artery stenosis. Carotid artery stenting (CAS) can reduce stroke risk, but variability in post-stenting health outcomes and their predictors are poorly understood. We examined 30-day post-CAS health status and derived its most important clinical predictors.
Methods The SAPPHIRE Worldwide Registry measured pre-procedural and 30-day health status for carotid artery stenosis patients undergoing transfemoral-CAS using the SF-36 or EQ-5D between 2010-2014. Four health status scores were calculated: SF-36 Mental Component Summary (MCS) and Physical Component Summary (PCS), EQ-5D Index Value and Visual Analogue Scale (VAS). Random Forest models ranked 66 pre-procedural candidate variables by relative importance in predicting 30-day post-CAS health status, stratified by symptomatic status. Variables with highest importance were used to develop predictive multivariable linear regression models. Model accuracy was assessed via Out of Bag accuracy and R-square, respectively.
Results Health status was assessed using the SF-36 in 3,017 patients and EQ-5D in 3,390 patients. Random Forest models demonstrated high accuracy (86.7% - 95.2%) and identified nine key predictors of post-stenting health status: pre-procedural health status (RI 100%), Modified Rankin Scale (RI 26.2-76.5%), NIH Stroke Scale (RI 12.1-28.0%), history of stroke (RI 9.2- 19.8%), congestive heart failure (RI 12.3-19.7%), spinal immobility (RI 6.7-31.0%), diabetes mellitus (RI 8.1-32.9%), severe pulmonary disease/COPD (RI 13.8-45.6%), and non-Hispanic/Latino ethnicity (RI 8.4-32.4%). Multivariable linear regression models explained ∼36- 61% of health status variance, with the asymptomatic SF-36 PCS model explaining 61%. SF-36 PCS and MCS models outperformed EQ-5D Index Value and VAS models regarding R-square and visual fit of observed vs. predicted values.
Conclusions We successfully derived prediction models for patient-centered outcomes following CAS which partially explained 30-day post-CAS health status outcomes. Pre-procedural health status, stroke scale scores, and medical comorbidities should be considered when discussing health status benefits in pre-CAS treatment decision discussions.
Competing Interest Statement
Dr. Smolderen reports unrestricted research grants from Abbott, Merck & Co., Inc., Shockwave Medical Inc., and Janssen Pharmaceutical Companies of Johnson Johnson. She is a consultant for Terumo, Cook Medical, Inc., NovoNordisk, and Happify. Dr. Mena-Hurtado reports grant funding from Shockwave Medical, Inc., Merck & Co., Inc. and is a consultant for Cook Medical, Inc., and Terumo. All other authors report no disclosures or conflicts of interest.
Clinical Trial
NCT00403078
Funding Statement
None
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This research was exempt from annual IRB review under section 45CFR46.104(4).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Data Availability
Data for this manuscript was obtained from the SAPPHIRE Worldwide Registry
